Targeting Conformational Activation of CDK2 Kinase

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and attractive targets for cancer therapy.
• Current CDK inhibitors targeting the ATP-binding site exhibit limited selectivity and can lead to drug resistance.
• Allosteric inhibitors offer a promising alternative by targeting protein conformational dynamics, potentially improving selectivity.

Purpose of the Study:

• To engineer a selective biosensor for CDK2 T-loop conformational changes.
• To identify novel allosteric inhibitors of CDK2 using the developed biosensor.
• To explore a new class of CDK inhibitors for cancer treatment.

Main Methods:

• Engineered a fluorescent biosensor to monitor CDK2 activation loop dynamics, independent of ATP binding.
• Screened a chemical library using the biosensor to identify modulators of CDK2 T-loop.
• Characterized the identified compounds for their binding and inhibitory activity against CDK2 and other kinases.

Main Results:

• Discovered quinacridine analogs that potently inhibit cancer cell proliferation and induce S/G2 phase arrest.
• Demonstrated that these compounds bind CDK2/Cyclin A, inhibit kinase activity, and compete with substrate binding, not ATP.
• Showed compounds dock onto the CDK2 T-loop and the lead compound inhibits CDK4/Cyclin D1 but not CDK1.

Conclusions:

• Developed a sensitive biosensor for identifying selective allosteric CDK inhibitors.
• Identified quinacridine analogs as a new class of CDK inhibitors targeting the T-loop.
• This strategy provides a novel approach for developing selective CDK-targeted cancer therapeutics.